
About Immunocore
Immunocore is a publicly listed company based in Abingdon (United Kingdom) founded in 2008 by Nicholas John Cross and George Kelly Martin. Developer of drugs based on T-Cell receptor technology for the treatment of cancer. Immunocore has raised $601.28 million across 9 funding rounds from investors including Lilly, WuXi AppTec and BlackRock. The company has 493 employees. Immunocore was last valued at $777.28 million in July 2015. Its website immunocore.com draws about 12 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is IMMUNOCORE LIMITED. Its competitors include Autolus, Achilles Therapeutics and LIfT Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Immunocore was founded in 2008 in Abingdon, United Kingdom, within the biotechnology sector focused on oncology. Proprietary ImmTAC molecules are developed to mobilize the immune system against cancer cells by targeting peptide-HLA complexes and triggering T-cell responses via anti-CD3 fragments. Operations center on advancing bi-specific immunotherapeutics, with the lead candidate IMCgp100 directed toward uveal melanoma treatment.
- Headquarters Abingdon, United Kingdom
- Employees 493
- Founders Nicholas John Cross, George Kelly Martin
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website immunocore.com
- Social LinkedIn X YouTube
- Legal Name Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
- Annual Revenue$400.95 M (USD)29.2as on Dec 31, 2025
- Net Profit-$35.6 M (USD)30.35as on Dec 31, 2025
- EBITDA-$42.19 M (USD)36.36as on Dec 31, 2025
- Total Equity Funding$601.28M (USD)
in 9 rounds
- Latest Funding Round$140M (USD), Post-IPO
Jul 2022
- InvestorsLilly
& 12 more
- Employee Count493
Apps and channels of Immunocore
its YouTube channel Immunocore has 156 subscribers and 16 videos.
Videos from Immunocore
The most watched videos on Immunocore's YouTube channel, Immunocore (156 subscribers). Click a video to play it here.
More on Immunocore.
Funding Insights of Immunocore
Immunocore has successfully raised a total of $601.28M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $140 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $601.28M
- Total Rounds 9
- Last Round Post-IPO β $140M
- First Round $37.78M
(Sep 2008)
- Investors Count 13
All 9 funding rounds of Immunocore with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $140M | Post-IPO | β | β | β |
| Feb 2021 | $15M | Post-IPO | β | β | β |
| Jan 2021 | $100M | Debt – Conventional | β | β | |
| Jan 2021 | $75M | Series C | β | BlackRock | β |
| Mar 2020 | $38.5M | Series B | β | β | β |
| Apr 2019 | $130M | Series B | β | General Atlantic | |
| Sep 2017 | $40M | Grant | β | β | |
| Jul 2015 | $320M | Series B | $777.28M | Malin PLC, Woodford Investment Management | |
| Sep 2008 | $37.78M | Series A | β | β | β |
| Date | Valuation | Stage |
|---|---|---|
| Jul 2015 | $777.28M | β’β’β’β’β’β’β’β’ |
Last known valuation $777.28M (Jul 2015). 13 investors in total: 13 institutional.
Investors in Immunocore
Immunocore has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, WuXi AppTec and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States | |
Companies developing T1D products are funded through venture philanthropy. | t1dfund.org | Boston, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Private equity investments in China are managed by TMCP. | terramagnumcap.com | Chaoyang, China | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 1988 | blackrock.com | New York, United States | |
CCB International is engaged in investment banking and financial services. | ccbintl.com.hk | Hong Kong, Hong Kong | ||
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
Provider of CRO and CDMO services | 2000 | wuxiapptec.com | Shanghai, China |
Investor details for Immunocore
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immunocore
62 people are tracked at Immunocore (41 in leadership, 6 in board & advisors, 15 in team); the tracked headcount is 493.
| Name | Role | Group |
|---|---|---|
Nicholas John Cross | Co-Founder | Leadership |
George Kelly Martin | Co-Founder | Leadership |
Lily Margaret Hepworth | Executive Director | Leadership |
Valerie Reynaert | Vice President Global Clinical Operations | Leadership |
Debra Nielsen | Chief of Staff | Leadership |
Tina St. Leger | Chief Human Resources Officer | Leadership |
Koustubh Ranade | SVP & Head Of Translational Medicine | Leadership |
Ralph Torbay | Chief Commercial Officer (cco) | Leadership |
Andrew Hooker | Senior Vice President, CMC & Supply Chain (immunocore Leadership Team) | Leadership |
Christina Sheil M.D. | VP Of Pharmacovigilance | Leadership |
Chris Conner | Senior Director, Oncology Account Management | Leadership |
Daniel Sum | Head, Pharmacovigilance | Leadership |
Kelly M. Armillotti | Director, Commercial Operations & Sales Force Effectiveness | Leadership |
Joann Suzich | Head of Research | Leadership |
Matt Newall | Director Global Procurement | Leadership |
Bahija Jallal | Chief Executive Officer | Leadership |
Mohammed Dar | Chief Medical Officer And Head Of Clinical Development | Leadership |
Annelise Vuidepot | CTO - Head Of Pipeline & Platform Research And UK Site Head | Leadership |
David Berman | Head of Research and Development | Leadership |
Mark Moyer | Senior Vice President -regulatory, Pv, Quality Assurance Departments, And Project Lead Kimmtrak At I | Leadership |
42 more people are available in the full profile.
Complete people profiles for Immunocore
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Immunocore
Immunocore is a publicly listed company on the NASDAQ with ticker symbol IMCR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Feb 2021
- Listed onNASDAQ: IMCR
- Listed entityImmunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
- Exchange sectorHealth technology
- ISINUS45258D1054
- Share price$27.82 (-4.2% on the day) · 2026-10-13
- Market capitalisation$1.43B
- EPS (diluted, trailing year)$-0.35
- Volume (last session)904,557
Financials of Immunocore
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $400.9M | -$35.6M | -$42.2M |
| 2024 | $310.3M | -$51.1M | -$66.3M |
| 2023 | $250.4M | -$55.5M | -$55.8M |
| 2022 | $177.1M | -$50.8M | -$56.4M |
| 2021 | $36.5M | -$180.9M | -$177.0M |
Detailed financial statements for Immunocore
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Immunocore
5 dated milestones of Immunocore across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Immunocore is founded.
- Funding First funding round of $37.8M.
- Milestone Reaches Minicorn status.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $140.0M.
Competitors of Immunocore
Immunocore has 3 listed competitors in our database, 3 of them funded. They include Autolus, Achilles Therapeutics and LIfT Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| autolus.com | 2015 | London, United Kingdom | $181.37M | 51 | Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | |
| achillestx.com | 2016 | London, United Kingdom | $241.98M | 118 | T-cell therapies targeting tumor neo-antigens for cancer are developed. | |
| liftbiosciences.com | 2016 | London, United Kingdom | $20.13M | 8 | Neutrophil-based cell therapies for solid tumors are developed. |
Detailed competitors of Immunocore
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Immunocore
The website of Immunocore (immunocore.com) receives about 11.9K visits a month and ranks #2,192,904 among all websites worldwide, #2,972 in Biotechnology and Pharmaceuticals.
- Monthly visits11.9K
▲ 8.8% vs previous month
- Unique visitors4.3K
per month
- Global rank#2,192,904
among all websites
- Category rank#2,972
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.8
- Average visit31 sec
- DevicesDesktop 44% Β· Mobile 56%
Websites whose visitors overlap most with Immunocore. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cytomx.com | 100% | 17.7K | #2,633,987 | View details | |
| curevac.com | 100% | 21.2K | #1,260,361 | View details | |
| pmlive.com | 96% | #627,237 | View details | ||
| pharmaphorum.com | 96% | 128.2K | #451,885 | View details | |
| qbiotics.com | 67% | 2.3K | #7,924,987 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 7 similar websites and full traffic analytics for Immunocore
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immunocore
Complete news archive for Immunocore
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunocore
Immunocore was founded in 2008.
Immunocore is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
Immunocore is a funded company, having raised a total of $601.28M across 9 funding rounds to date. The company's 1st funding round was a Series A of $37.78M, raised on Sep 2008.
Immunocore has 493 employees.
Annual revenue of Immunocore is $400.95M as on Dec 31, 2025.
Immunocore was founded in 2008 in Abingdon, United Kingdom, within the biotechnology sector focused on oncology. Proprietary ImmTAC molecules are developed to mobilize the immune system against cancer cells by targeting peptide-HLA complexes and triggering T-cell responses via anti-CD3 fragments. Operations center on advancing bi-specific immunotherapeutics, with the lead candidate IMCgp100 directed toward uveal melanoma treatment.
Immunocore's top competitors include Achilles Therapeutics, Autolus and LIfT Biosciences.
Yes, Immunocore is publicly traded on NASDAQ under the ticker symbol IMCR.
Immunocore has 13 investors. Key investors include Lilly, WuXi AppTec, BlackRock, General Atlantic, and Gates Foundation.
The valuation of Immunocore is $777.28M as of Jul 2015.
Immunocore operates through Immunocore Limited.
